SANOFI SECURES ENTRY INTO U.S. PHARMACEUTICAL MARKET WITH BUY- OUT OF Rx JOINT VENTURE WITH STERLING; $1.68 BIL. IN CASH PLUS INTEREST IN EUROPEAN OTCs IS PRICE
Executive Summary
Sanofi is paying Kodak $1.68 bil. in cash to hold on to its entry into the U.S. prescription drug market through Sterling.